Angioedema Management

Introduction to Angioedema

Angioedema typically presents with asymmetric, non-dependent swelling, prominent involvement of face and tongue, and possible involvement of other areas, generally not pruritic, with increased plasma bradykinin levels in affected patients, and can develop even after many years of continuous therapy, with a bradykinin-mediated mechanism rather than histamine-mediated 1

Higher risk populations for ACE inhibitor-associated angioedema include African American/Black patients, smokers, female patients, older individuals, and non-diabetic patients, according to the American Academy of Allergy, Asthma, and Immunology 1

Most patients who have experienced ACEi-induced angioedema can safely use ARBs without recurrence of angioedema, though a modest risk (2-17%) of recurrent angioedema exists, as recommended by the American Academy of Allergy, Asthma, and Immunology 1
Calcium channel blockers represent a safe alternative with no increased risk of angioedema, as supported by the American Heart Association 2, 3 and American College of Cardiology 3
Alternative antihypertensive treatments should be considered for patients who have experienced ACE inhibitor-induced angioedema, according to the American Academy of Allergy, Asthma, and Immunology 1, American Heart Association 2, 3, and American College of Cardiology 3

For acute attacks of hereditary or acquired C1 inhibitor deficiency, C1 inhibitor concentrate (20 U/kg IV) is recommended by the American Academy of Allergy, Asthma, and Immunology 1
For long-term prophylaxis of hereditary or acquired C1 inhibitor deficiency, plasma-derived nanofiltered C1INH (1000 U IV every 3-4 days) or anabolic steroids (for adults) with regular monitoring for hepatic inflammation may be used, as suggested by the British Association of Dermatologists 4
Tranexamic acid is the most widely used and successful medication for idiopathic angioedema without weals, as recommended by the British Association of Dermatologists 4

Patients who have experienced ACE inhibitor-induced angioedema should not be rechallenged with another ACE inhibitor and should be informed about the risk of recurrent angioedema even after ACE inhibitor discontinuation, with clear documentation of the reaction in all medical records and consideration of medical alert identification for severe cases, as recommended by multiple guideline societies and authorities, including the American Academy of Allergy, Asthma, and Immunology 1, American College of Emergency Physicians 1, and European Academy of Allergy and Clinical Immunology 1
Antihistamines, corticosteroids, and epinephrine are not effective for bradykinin-mediated angioedema, according to the American Academy of Allergy, Asthma, and Immunology 1
Alternative treatments, such as icatibant (a bradykinin B2 receptor antagonist), fresh frozen plasma, and C1 esterase inhibitor concentrate, have shown potential benefit, although more research is needed to confirm their efficacy 1